Emerging nanopharmaceuticals and nanonutraceuticals in cancer management
Nanotechnology is the science of nanoscale, which is the scale of nanometers or one
billionth of a meter. Nanotechnology encompasses a broad range of technologies, materials …
billionth of a meter. Nanotechnology encompasses a broad range of technologies, materials …
Ultrasound-responsive materials for drug/gene delivery
X Cai, Y Jiang, M Lin, J Zhang, H Guo, F Yang… - Frontiers in …, 2020 - frontiersin.org
Ultrasound is one of the most commonly used methods in the diagnosis and therapy of
diseases due to its safety, deep penetration into tissue, and non-invasive nature. In the …
diseases due to its safety, deep penetration into tissue, and non-invasive nature. In the …
Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives
JB Wang, X Huang, FR Li - Cancer communications, 2019 - Springer
Lung cancer is the leading cause of cancer mortality worldwide. Dendritic cells (DCs) are the
key factors providing protective immunity against lung tumors and clinical trials have proven …
key factors providing protective immunity against lung tumors and clinical trials have proven …
Stimuli-responsive drug delivery systems for the diagnosis and therapy of lung cancer
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death
worldwide. Numerous drugs have been developed to treat lung cancer patients in recent …
worldwide. Numerous drugs have been developed to treat lung cancer patients in recent …
Enhanced cellular uptake and gene silencing activity of survivin-siRNA via ultrasound-mediated nanobubbles in lung cancer cells
Purpose Paclitaxel is a first-line drug for the therapy of lung cancer, however, drug
resistance is a serious limiting factor, related to overexpression of anti-apoptotic proteins like …
resistance is a serious limiting factor, related to overexpression of anti-apoptotic proteins like …
Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells
F Gao, M Li, X Yu, W Liu, L Zhou… - Journal of Cellular and …, 2021 - Wiley Online Library
Dysfunction of epidermal growth factor receptor (EGFR) signalling plays a critical role in the
oncogenesis of non–small‐cell lung cancer (NSCLC). Here, we reported the natural product …
oncogenesis of non–small‐cell lung cancer (NSCLC). Here, we reported the natural product …
Revolutionizing Lung Cancer Treatment: Nanotechnology-Driven Advances in Targeted Drug Delivery and Novel Therapeutic Strategies
S Shojaei, M Pourmadadi, M Homayoonfal… - Journal of Drug Delivery …, 2024 - Elsevier
Lung cancer, the second leading cause of cancer-related mortality and incidence globally,
presents a formidable challenge with an estimated 238,340 new cases and 127,070 deaths …
presents a formidable challenge with an estimated 238,340 new cases and 127,070 deaths …
Octaarginine functionalized nanoencapsulated system: In vitro and in vivo evaluation of bFGF loaded formulation for wound healing
Despite all treatment efforts, diabetic wounds are still a major health concern that needs to
be solved. Growth factor-based therapeutic approaches offer promising results for wound …
be solved. Growth factor-based therapeutic approaches offer promising results for wound …
Preparation optimization of bovine serum albumin nanoparticles and its application for siRNA delivery
Y Wang, S Chen, X Yang, S Zhang… - … Design, Development and …, 2021 - Taylor & Francis
Background siRNA brings hope for cancer therapy. However, there are many obstacles for
application of siRNA in clinical. Because of the excellent biocompatibility, non-toxicity and …
application of siRNA in clinical. Because of the excellent biocompatibility, non-toxicity and …
Discovery and Mechanistic Study of Mycobacterium tuberculosis PafA Inhibitors
C Li, S Liu, B Dong, C Li, L Jian, J He… - Journal of Medicinal …, 2022 - ACS Publications
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis (Mtb) and is ranked as
the second killer infectious disease after COVID-19. Proteasome accessory factor A (PafA) is …
the second killer infectious disease after COVID-19. Proteasome accessory factor A (PafA) is …